Prostate enriched long non-coding RNA (PSLNR)

Prostate enriched long non-coding RNA (PSLNR, LA16c-83F12.6) is a non-protein coding RNA species annotated based on expression profiling that indicates high specificity for prostate tissue[1][2]. While the biology of lncRNAs in prostate cancer is a major research area, PSLNR itself is not widely reported in therapeutic literature and has not been functionally characterized or proposed as a drug target in authoritative sources[1][2][5][6]. Most publications on prostate cancer-related lncRNAs discuss molecules such as PCA3, PART1, PRCAT38, and ARLNC1, with established disease and mechanistic roles[2][5][6]. PSLNR may serve as a candidate for further study as a potential tissue-specific biomarker, but currently there is no evidence supporting its role in cancer pathogenesis, as a receptor, or as a drug target. Based on available data, information remains insufficient to classify this molecule beyond a candidate long non-coding RNA with possible prostate-specific expression. If you need structured information for another, more widely validated prostate cancer-associated lncRNA (e.g., PCA3, PART1, PRCAT38), more details are available in the literature[2][5][6].

Other names

LA16c-83F12.6prostate-specific lncRNAPSLNR